Pegasus Biotech Inc. has announced that they have redesigned the way plasmid DNA replicates, allowing for greater control over when and how DNA is produced. This new technology, called BPE plasmid, utilizes a patented origin that can lay dormant during fermentation and trigger replication at high cell densities, resulting in significantly higher replication levels compared to existing technology.
One of the key benefits of BPE plasmid is its lack of an antibiotic resistance selection marker and minimal bacterial sequences, with less than 1,000 base pairs. This makes it ideal for applications where cost of goods sold and patient safety are important factors. Additionally, the technology offers enhanced expression, with cells transfected with BPE plasmid showing up to 7 times more expression than conventional plasmid backbones.
Pegasus Biotech aims to facilitate the development and market entry of innovative biopharmaceutical and vaccine products by providing seed-to-formulation process development and associated analytical development services. They specialize in ensuring that client projects comply with global regulations and result in commercially viable products. For more information on Pegasus’ services, visit their website.
Daniel Wilson, the COO of Pegasus Biotech, emphasized the transformational nature of this technology in applications where cost of goods sold and patient safety are important factors. The project required low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker – all characteristics of this technology.
Pegasus Biotech Inc., a full-service biotechnology contract research organization specializing in vaccine and biopharmaceutical development, is global leaders in DNA vaccine development. For media inquiries please contact Daniel Wilson at Pegasus Biotech Inc via email or visit www.pegasusbio.com